National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
about
DENTAL CONSIDERATIONS FOR LEUKEMIC PEDIATRIC PATIENTS: AN UPDATED REVIEW FOR GENERAL DENTAL PRACTITIONERPhysical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patientsNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportFibrotic and sclerotic manifestations of chronic graft-versus-host diseaseRationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHDTreatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statementPatient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD ConsortiumCurrent issues in chronic graft-versus-host disease.Graft-versus-host disease: state of the science.Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD.Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord bloodMethotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Stem cells in clinical practice: applications and warnings.Have we made progress in the management of chronic graft-vs-host disease?How we treat chronic graft-versus-host disease.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.Treatment of chronic graft-versus-host disease: Past, present and future.A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials.Umbilical cord blood transplantation for children with thalassemia and sickle cell disease.Progress in chronic graft-versus-host disease.Brazilian workshop model to train investigators in chronic graft-versus-host disease clinical trials according to the 2005-2006 National Institutes of Health recommendations.Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantationClinical benefit of response in chronic graft-versus-host diseasePredictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease.Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical TrialsStandardizing chronic graft-versus-host disease.Fulminant gastrointestinal graft-versus-host disease concomitant with cytomegalovirus infection: case report and literature reviewChronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials.Murine models of chronic graft-versus-host disease: insights and unresolved issues.Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom.Study design and endpoints in graft-versus-host disease.Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
P2860
Q26775805-1CA5AB0F-56AE-45CD-A977-F4B89A85891BQ26787230-69976B5B-A41A-4ADF-A82B-FF5C39E6E831Q26827651-D08D01DB-AD97-4137-88F2-92D344E91499Q27024147-50EDCF23-22FD-4732-845E-AA2ACFECB405Q33591662-3D8218A1-B08C-4CCC-AF84-258FAFB47430Q33608255-BAB8B758-4643-4F40-98B3-2C1F427DA214Q33622648-6A2708E8-A5A6-45B3-B983-DB52C11DD5C1Q33830644-0E8C853F-BCDD-43B2-8937-05250D2691BFQ33917187-D35263DB-9C1C-4885-A403-946CE3B9103CQ33977923-310BC7CC-EC33-46EE-8AE0-2EBCC05DACA3Q34144161-E8F5B2CB-FE36-4C89-9045-C00B7F06DEAEQ34320319-EBFA9475-88F3-454E-80BC-C9EFA856B736Q34374133-00387330-5E08-48E2-A1FE-DED8B417073CQ34487408-14C5ACE1-3BB8-4CC4-9448-4E28DFDC91F9Q34552765-ED3208E9-4654-4533-B2A3-DD2BD40EFA04Q34644980-A91030D5-6409-4EBA-80B8-3DFD0AA0DA80Q35004923-BAF799A7-2237-45B7-80AC-5628D24B056AQ35078368-CF1FD636-360F-4F62-A092-6899194FC04EQ35172772-BAB514FF-FD65-4F8F-8FC0-26C4B2C03831Q35524687-227FAB31-226F-4011-9117-3BB8731C4E70Q35748144-C87B662E-EC89-4010-A4D0-CB84F6BB7EF8Q36090062-AC66FF4D-6EBD-486D-9C63-65DCA41E8719Q36153593-4DFA8617-78F1-4072-9011-17CD6C8E2BC7Q36153664-D407C55E-DDD4-4F6C-A4D4-584023370209Q36186850-21ACE1C1-3A5F-421D-9AB7-51BD36874988Q36236504-2D55150E-EB39-4DA9-B944-675B622EF64AQ36443116-B4836859-2456-4004-9AD7-2C49DF55CA7CQ36498345-64DA9BF4-6CFA-4842-8DC8-025B4D94DD7EQ36540762-6947CEF2-9F27-4C24-830D-91012CE42AEAQ36572516-2680167D-E88A-4EB5-BD26-A99EECC51B76Q36572542-1CD95048-A62D-4E12-8B3F-8338EAE36870Q36596493-7EFE3FED-F2C5-46EA-93DE-867896BD2999Q36645730-9BE856B3-86F2-4FC9-BFE9-546E63C9A789Q36707816-C7D68AAF-196B-4C66-960B-BB9B427DB0C2Q36709850-38868691-E548-4B5D-9339-E7A186B5F8F9Q36747224-7BE443C9-972F-423C-8007-363AE507CB10Q36788458-654025F0-5338-4738-8CAE-5A5E57731304Q36790424-6A44B7BA-613E-4247-ADD1-715416C77707Q36925994-95462C54-7CE4-4186-BDB7-F068064769A1Q37113099-DF67A993-A10B-4403-95D9-D7EC16C5878A
P2860
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
National Institutes of Health ...... l Trials Working Group report.
@ast
National Institutes of Health ...... l Trials Working Group report.
@en
type
label
National Institutes of Health ...... l Trials Working Group report.
@ast
National Institutes of Health ...... l Trials Working Group report.
@en
prefLabel
National Institutes of Health ...... l Trials Working Group report.
@ast
National Institutes of Health ...... l Trials Working Group report.
@en
P2093
P1476
National Institutes of Health ...... l Trials Working Group report.
@en
P2093
Alexandra H Filipovich
Ann Farrell
Daniel Couriel
Daniel Weisdorf
Design of Clinical Trials Working Group
Donna Przepiorka
Georgia B Vogelsang
J Douglas Rizzo
Kirk R Schultz
Mary E D Flowers
P304
P356
10.1016/J.BBMT.2006.03.004
P577
2006-05-01T00:00:00Z